The impact of secondary hyperparathyroidism on the efficacy of antiresorptive therapy.

BACKGROUND: The aim of the present study was to assess whether the efficacy of bisphosphonate treatment is influenced by PTH levels measured in newly diagnosed osteoporotic patients and to identify the threshold value, beyond which PTH level negatively influences therapeutic efficacy. METHODS: One hundred and thirty-eight osteoporotic patients were enrolled into the study. All subjects underwent laboratory screening, bone densitometry with DEXA, and x-ray imaging. The changes in bone density were evaluated after a mean follow-up period of 13.37 ± 1.29 months. Correlation analysis was performed on the clinical data of patients, the percentage changes of BMD values, and the PTH levels measured at the beginning of study, using SPSS software. RESULTS: The mean age of the subjects was 64.82 ± 10.51 years, and the female-to-male ratio was 116/22. Baseline BMD value measured with AP DEXA scanning was 0.854 ± 0.108 g/cm(2) in the L(1-4) vertebrae and 0.768 ± 0.115 g/cm(2) in the left femoral neck. By the end of the follow-up period, these values changed to 0.890 ± 0.111 g/cm(2) and 0.773 ± 0.111 g/cm(2), respectively. We found a statistically significant, negative correlation between PTH levels and the percentage changes of lumbar BMD values measured at the end of the follow-up (correlation coefficient R(2) = 0.121, p < 0.0001). The analysis of frequency histograms suggested that negative effects on bone might be expected above a PTH level of 60 pg/mL (7.3 pmol/L). CONCLUSION: Our findings imply that a baseline PTH level over 60 ng/mL can reduce the efficacy of bisphosphonate treatment.

Overcoming resistance to bisphosphonates through the administration of alfacalcidol: results of a 1-year, open follow-up study.

This study intended to determine whether the replacement of vitamin D3 with alfacalcidol results in any bone mineral density (BMD) increase in 76 patients unresponsive to the combination of alendronate and conventional vitamin D3 treatment. In these patients the conventional vitamin D3 had been replaced with alfacalcidol (0.5 µg/day), and then the patients were followed up for a year. After treatment for 1 year, Wilcoxon test revealed a small but statistically significant (P < 0.001) increase in the BMD values of the forearm and lumbar vertebrae, in the serum calcium and urinary calcium/creatinine ratio in first-voided morning urine. However, the serum alkaline phosphatase activity, phosphorus, parathormone, osteocalcin levels and the urinary d-pyr/creatinine ratio decreased significantly (P < 0.001). As suggested by our results, combination therapy with alendronate and alfacalcidol increases bone density and improves the biochemical markers of bone turnover, without any substantial increase in the incidence of adverse effects.

High prevalence of oesophageal involvement in patients with undifferentiated connective tissue disease using radionuclide oesophageal transit scintigraphy.

AIM: To look for the frequency of oesophageal dysfunction using radionuclide oesophageal transit scintigraphy in 145 patients with undifferentiated connective tissue disease (UCTD); to seek the correlation between the clinical/laboratory data and scintigraphic alterations; and to determine predictive value of radionuclide oesophageal transit scintigraphy for evolution to established connective tissue disease (CTD). METHOD: One hundred and forty-five patients with UCTD were examined by 99mTc-DTPA oesophageal transit scintigraphy. The intraoesophageal transport of the radiopharmaceutical was followed and imaged by a gamma camera, a series of 128 x 128 images were stored and evaluated. The correlation between the scintigraphic data and clinical and laboratory parameters was analysed statistically. RESULTS: Unequivocally positive scintigraphy, indicative of motor abnormality was found in 46% of patients (66), 71% (47) of whom were totally asymptomatic. Significant correlation was found between the presence and severity of scintigraphic alterations and antinuclear antibodies, the anti-beta2GPI, IgM, IgG, the aCL antibody positivity, and the skin symptoms. Scintigraphic positivity was significantly more frequent in patients evolving to definitive CTD (P = 0.0178), and abnormal scan predisposed to transition into the definitive CTD (odds ratio, 2.292; CI, 1.610-4.525). Its cumulative positive predictive value was found to be 43% and cumulative negative predictive value 73% with regard to the development of a definitive CTD. CONCLUSION: Our results show that scintigraphic alterations together with clinical and laboratory alterations can help the clinician in the prediction of final outcome.

[Modern treatment of rheumatoid arthritis]. / A rheumatoid arthritis korszeru kezelése.

Modern treatment of rheumatoid arthritis. Rheumatoid arthritis is a chronic inflammatory disease of unknown etiology, which is characterised by pain, loss of capability to work, in severe cases the life expectancy is also reduced. The disease cannot be cured with current therapeutic possibilities, but complaints can be reduced, the destruction can be retarded. The treatment is more efficient in the early stage of the disease, but early diagnosis is difficult because of insidious onset and limited sensitivity of diagnostic methods. The complaints can be alleviated by nonsteroidal anti-inflammatory drugs and transient glucocorticoid treatment, but risk of continuous glucocorticoid therapy is significant. To prevent structural damage disease modifying antirheumatic drugs are used. Out of these methotrexate is the most effective and it is well tolerated. Destruction of the joints is the consequence of inflammation, so intensity of drug treatment must be adjusted to inflammatory activity. For monitoring in clinical practice the composite index disease activity score is recommended. To achieve the reduction of inflammatory activity the dosage of disease modifying drugs can be increased, they can be switched or combined, and continuous glucocorticoid treatment can be started. In cases refractory to conventional treatment it is possible to inhibit the activity of proinflammatory cytokines, which play a pivotal role in pathomechanism of rheumatoid arthritis. In synovitis limited to one joint intraarticular glucocorticoid injection can be given, in refractory cases synovectomy is indicated. Destruction of the joints can be partially corrected by exercise, orthoses and after all with surgery.

[Interferon induced psoriatic arthritis in a patient with renal cancer]. / Interferon altal indukált arthritis psoriatica vesecarcinomás betegben.

Interferon induced psoriatic arthritis in a patient with renal cancer. The authors describe a patient's history, whose alpha interferon treatment was started after the nephrectomy because of renal tumor spreading into the inferior caval vein. One week after the starting the interferon treatment typical psoriatic plaques and acute polyarthritis developed with prominent inflammatory signs. The cessation of interferon treatment, administration of systemic and intraarticular steroid, non steroid antiinflammatory drug and combined disease modifying drug therapy resulted in termination of skin symptoms and definitive relief in articular complaints. Moreover there were found laboratory alterations characteristic for autoimmune thyroiditis as well. The authors attributed both manifestations to rare immunological side effects of interferon treatment and survey the relevant literature.